Source: CureToday articles
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
Recent Content
- “Chillin’ Out” and Finding Our Cancer Community
- AAN 2025: Pharmacists Play Critical Role in Monitoring, Managing Lecanemab Therapy
- Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
- Risk of lymphoid malignancy associated with cancer predisposition genes
- Large-scale human myeloma cell line small molecule compound screen dataset
- Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
- PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Non-Diabetics
- AAN 2025: Insights on Pediatric Multiple Sclerosis Treatment and Management
- Illuminating Compassion in Cancer Care
- Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program